Cargando…

Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection

The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinate...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimeglio, Chloé, Migueres, Marion, Bouzid, Naémie, Chapuy-Regaud, Sabine, Gernigon, Caroline, Da-Silva, Isabelle, Porcheron, Marion, Martin-Blondel, Guillaume, Herin, Fabrice, Izopet, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506424/
https://www.ncbi.nlm.nih.gov/pubmed/36146626
http://dx.doi.org/10.3390/vaccines10091548
_version_ 1784796719473491968
author Dimeglio, Chloé
Migueres, Marion
Bouzid, Naémie
Chapuy-Regaud, Sabine
Gernigon, Caroline
Da-Silva, Isabelle
Porcheron, Marion
Martin-Blondel, Guillaume
Herin, Fabrice
Izopet, Jacques
author_facet Dimeglio, Chloé
Migueres, Marion
Bouzid, Naémie
Chapuy-Regaud, Sabine
Gernigon, Caroline
Da-Silva, Isabelle
Porcheron, Marion
Martin-Blondel, Guillaume
Herin, Fabrice
Izopet, Jacques
author_sort Dimeglio, Chloé
collection PubMed
description The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinated healthcare workers, some of whom had been previously infected by SARS-CoV-2. The median follow-up was 179 days (IQR: 171–182) after blood collection. We detected 88 SARS-CoV-2 Omicron infections during the follow-up period, 55 (62.5%) with SARS-CoV-2 BA.1, and 33 (37.5%) with SARS-CoV-2 BA.2. A neutralizing antibody titer below 8 provided no protection against a BA.1 infection, a titer of 16 or 32 gave 73.2% protection, and a titer of 64 or 128 provided 78.4% protection. Conversely, the BA.2 infection rate did not vary as a function of anti-BA.2 neutralizing antibody titers. Binding antibody concentrations below 6000 BAU/mL provided no protection against Omicron BA.1 infection, 6000–20,000 BAU/mL provided 55.6% protection, and 20,000 or more provided 87.7% protection. There was no difference in BA.2 infection depending on the binding antibody concentration. Further studies are needed to investigate the relationship between antibody concentrations and infection with the Omicron BA.4/5 variants that are becoming predominant worldwide.
format Online
Article
Text
id pubmed-9506424
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95064242022-09-24 Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection Dimeglio, Chloé Migueres, Marion Bouzid, Naémie Chapuy-Regaud, Sabine Gernigon, Caroline Da-Silva, Isabelle Porcheron, Marion Martin-Blondel, Guillaume Herin, Fabrice Izopet, Jacques Vaccines (Basel) Article The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinated healthcare workers, some of whom had been previously infected by SARS-CoV-2. The median follow-up was 179 days (IQR: 171–182) after blood collection. We detected 88 SARS-CoV-2 Omicron infections during the follow-up period, 55 (62.5%) with SARS-CoV-2 BA.1, and 33 (37.5%) with SARS-CoV-2 BA.2. A neutralizing antibody titer below 8 provided no protection against a BA.1 infection, a titer of 16 or 32 gave 73.2% protection, and a titer of 64 or 128 provided 78.4% protection. Conversely, the BA.2 infection rate did not vary as a function of anti-BA.2 neutralizing antibody titers. Binding antibody concentrations below 6000 BAU/mL provided no protection against Omicron BA.1 infection, 6000–20,000 BAU/mL provided 55.6% protection, and 20,000 or more provided 87.7% protection. There was no difference in BA.2 infection depending on the binding antibody concentration. Further studies are needed to investigate the relationship between antibody concentrations and infection with the Omicron BA.4/5 variants that are becoming predominant worldwide. MDPI 2022-09-17 /pmc/articles/PMC9506424/ /pubmed/36146626 http://dx.doi.org/10.3390/vaccines10091548 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dimeglio, Chloé
Migueres, Marion
Bouzid, Naémie
Chapuy-Regaud, Sabine
Gernigon, Caroline
Da-Silva, Isabelle
Porcheron, Marion
Martin-Blondel, Guillaume
Herin, Fabrice
Izopet, Jacques
Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
title Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
title_full Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
title_fullStr Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
title_full_unstemmed Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
title_short Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
title_sort antibody titers and protection against omicron (ba.1 and ba.2) sars-cov-2 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506424/
https://www.ncbi.nlm.nih.gov/pubmed/36146626
http://dx.doi.org/10.3390/vaccines10091548
work_keys_str_mv AT dimegliochloe antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT migueresmarion antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT bouzidnaemie antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT chapuyregaudsabine antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT gernigoncaroline antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT dasilvaisabelle antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT porcheronmarion antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT martinblondelguillaume antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT herinfabrice antibodytitersandprotectionagainstomicronba1andba2sarscov2infection
AT izopetjacques antibodytitersandprotectionagainstomicronba1andba2sarscov2infection